Pharma Manufacturing Business Telangana: Bulk Drug Park Guide
Pharma Manufacturing Business Telangana: Bulk Drug Park Guide Read More »
Pharma Manufacturing Business Telangana The Hyderabad alone produces about one third of India’s output of bulk drugs and APIs, with the core of these activities being Genome Valley and a pharma manufacturing base, which has been created over 30 years. It’s actually this concentration that makes the pharma manufacturing business that the Telangana entrepreneurs think about today appear daunting from the exterior: Dr. Reddy’s, Divi’s Laboratories and Hetero already possess the cake. But the state’s own Bulk Drug Park initiative, which has been aided by capital subsidy from the central government, has been created because the policy makers have realised that there is a room for new and specific players in the market, apart from the giants who are already working on a large scale. It is not an opportunity for a founder looking for a product for which every other unit in Hyderabad is doing business. It’s an invitation for one trouble-prone founder to focus on a single facet — one intermediate, one niche API, one contract manufacturing partnership — within a regulatory framework, a workforce, and a buyer base that other states take years to develop. Read the Complete Book Here: Business Ideas for Startup in Drugs & Pharmaceutical Industry with Project Profiles Why Telangana’s Pharma Cluster Is a Genuine Opening Get started with talent density. An advantage for Hyderabad over the pharma companies that have not built their capacity with API and formulation manufacturing in the city, is that a new startup can easily find experienced process chemists, regulatory affairs personnel and quality control staff, without having to import them from across the country. Add to this the government’s support. The special Bulk Drug Park developed with central PLI linked capital subsidy and allotted through Telangana State Industrial Infrastructure Corporation has plug and play infrastructure with shared effluent treatment specifically for API and intermediate manufacturing thereby reducing capex and approval time for the units to be located inside the park. The state’s own industrial policy with a focus on the pharmaceutical sector has another layer of capital and power tariff benefits that sit on top of central schemes implemented through the Ministry of Micro, Small and Medium Enterprises. The basic intermediate manufacturing unit costs start around fifteen to two dozen crore rupees for two hundred to three hundred tonnes per year, while API manufacturing for regulated markets is thirty to fifty crore rupees based on stringent quality and validation regulations. It takes around 10-14 months for the Telangana State Pollution Control Board to approve licenses and the Central Drugs Standard Control Organisation for drug manufacturing to approve infrastructure, specifically Bulk Drug Park. Business Selection Logic The margin structure is as elsewhere in the bulk drug industry in India: commodity intermediates, which a handful of existing firms in Hyderabad produce, trade at 12 to 18% margins, while specialty intermediates or niche APIs that cater to a single innovator molecule trade at 25 to 35%. The pharma cluster in Telangana is scalable because of the presence of well established buyers. A founder can launch with one multipurpose batch reactor, test one or two products with a local formulation company that doesn’t have to look far to find a qualified supplier, and then expand when repeat orders are received and the product has been proven to be in demand. The same risks identified in bulk drug manufacture in the country, such as regulatory clearance timelines and buyer concentration, apply in Telangana, however, the buyer search risk that the founders of companies in less pharma-dense states face is significantly less in Telangana due to the high concentration of buyers of bulk drugs in the state. Get Detailed Project Report (DPR): Business Opportunities in Telangana – Startup & Entrepreneurship Guide Product and Project Opportunities Worth Evaluating Antibiotic and Antiviral Intermediates Antibacterial and antiviral intermediates are being used by Hyderabad’s formulation units all the time and also the volume of customers within the state is such that if a new intermediate manufacturer wants to find a customer, they have to look within 50 km of Hyderabad. The capex for a plant of 150-250 tonne per annum is 18-25 crore rupees. The margins range from eighteen to twenty-two percent after the quality certification process with a formulation buyer is completed, which is quicker in Telangana than states with lesser concentration of pharma buyers because of their prior understanding of the qualification of suppliers. Contract Manufacturing for Global Innovator Companies With its proven regulatory track record, Telangana is a logical base for the CRAMS approach of contract manufacturing, offering global innovator pharma companies to explore India as a production partner for complex intermediates. A separate unit – one with capex of 12 to 20 crore rupees – enters into multi-year supply contracts instead of looking for volumes in the spot market. The margins are 22-28 per cent and the existing standing that Hyderabad has with the regulatory authorities is a good advantage in terms of trust building for the buyer than if the founder was coming from a lesser- established pharma hub. Niche API Manufacturing for Regulated Export Markets The best chance for a founder to carve out a niche in the Telangana pharma market is niche APIs which are molecules with a small number of qualified global manufacturers. A dedicated facility, the capex is in the range of Rs. 30 to 40 crore, which takes into consideration quality and validation infrastructure requirements, directly targets export formulation buyers in regulated markets. Once a Drug Master File (DMF) is filed and approved, the margins are twenty-eight to thirty-five percent, but the filing of a DMF takes between twelve to twenty-four months. Related Article: India’s ₹27,000 Crore API Import Problem Is Your Biggest Business Opportunity Pharma Packaging and Ancillary Component Manufacturing In addition to direct drug production, Telangana’s pharma density ensures a consistent demand for such special packaging and blister components, as well as ancillary manufacturing that every formulation and API unit in the state will need. The dedicated line requires capes expenditure of Rs 8-12







